OZEM GLP-1 & Weight Loss ETF

Invest in the weight loss drug revolution with the Roundhill GLP-1 & Weight Loss ETF (OZEM). Gain exposure to weight loss stocks tackling obesity and supporting weight loss through ground-breaking drug development and innovation.

Top 5 Holdings

(as of 05/21/2024)

Eli Lilly & Co logo
Novo Nordisk A/S logo
Innovent Biologics Inc logo
Zealand Pharma A/S logo
Chugai Pharmaceutical Co Ltd logo

Overview

Roundhill believes that weight loss drugs, including GLP-1 agonists, represent one of the most revolutionary advancements in the global pharmaceuticals industry. The Roundhill GLP-1 & Weight Loss ETF (“OZEM”) is the world’s first GLP-1 ETF. OZEM is an actively-managed ETF.

Why OZEM?

Obesity Epidemic - Global obesity rates have nearly tripled since 1975 and are projected to impact over half the population by 2035.1

Revolutionary Drugs - Groundbreaking GLP-1 treatments, such as Ozempic, Wegovy, and Zepbound, are leading medical advancements in weight management.2

Market Growth - Goldman Sachs Research forecasts that the obesity treatment market could expand by more than 16 times its current size to reach $100 billion by 2030.3

1WHO/Goldman Sachs Research; 2Stifel, “Obesity drug review”, market update July 1st, 2023, 3Goldman Sachs Research.

Forecasts are inherently limited and should not be relied upon when making investment decisions. There is no guarantee the sector will experience projected growth. In addition, there is no guarantee it will translate to positive fund performance.

Fund Details

Ticker OZEM
Primary Exchange Nasdaq
Expense Ratio 0.59%
AUM
Launch 5/21/24
# of Holdings
ETF Options No
CUSIP 77926X882
ISIN US77926X8829
Shares Outstanding
Management Style Active

Holdings

Top Holdings

Name Ticker Weight
Name Weight

ETF holdings and allocations are subject to change at any time and should not be interpreted as an offer of these securities.

Performance

As of TBD

As of TBD

 
Closing Price
Change ($)
Change (%)
1 Year (as of )
3 Year (as of )
5 Year (as of )
Since Inception (as of )
30-Day Median Bid/Ask Spread
 
Net Asset Value
Change ($)
Change (%)
30-Day Median Bid/Ask Spread

The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance data quoted. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost. Returns less than one year are not annualized. For the most recent month-end performance, please call (855) 561-5728. You cannot invest directly in an index. Shares are bought and sold at market price (closing price), not net asset value (NAV), and are individually redeemed from the Fund. Market performance is determined using the Primary Exchange official closing price. Brokerage commissions will reduce returns.

Distributions

Yields

As of 5/21/24

30-Day SEC Yield*
Distribution Frequency Annual

*30-Day SEC Yield: Yield calculation that reflects the dividends and interest earned during the period after the deduction of the fund’s expenses. It is also referred to as the "standardized yield".

Distribution Calendar

Declaration Ex Date Record Date Pay Date

Distribution History

Declaration Ex Date Record Date Pay Date Amount Paid

Premium/Discount

FAQ

When did the Roundhill GLP-1 & Weight Loss ETF (Nasdaq: OZEM) launch?

OZEM began trading on May 21, 2024.

What are the fees for the Roundhill GLP-1 & Weight Loss ETF?

The Fund’s gross expense ratio is 0.59% per year.

Can I trade options on the Roundhill GLP-1 & Weight Loss ETF?

No, options trading is not yet available for OZEM.

Is the Roundhill GLP-1 & Weight Loss ETF actively managed?

Yes, our Investment Committee is responsible for security selection.

What types of companies are included in the Roundhill GLP-1 & Weight Loss ETF?

The OZEM ETF’s portfolio includes companies actively involved in GLP-1 & Weight Loss, including:

  • Diversified GLP-1 Therapeutics: large companies involved in the production or sale of pharmaceutical drugs designed for weight loss and anti-obesity related to GLP-1 drugs, in addition to other verticals of therapeutics.
  • GLP-1 Therapeutics: companies involved in the production or sale of pharmaceutical drugs designed for weight loss and anti-obesity related to GLP-1 drugs.
  • Other Weight Loss Enablers: companies involved in the production or sale of pharmaceutical drugs designed for weight loss and anti-obesity treatments unrelated to GLP-1 drugs.
  • Supply Chain Enablers: companies that support the manufacturing and distribution of GLP-1 and weight loss drugs.

What are GLP-1 Drugs?

GLP-1 receptor agonists represent a transformative advancement in the fight against obesity, a growing global health crisis. These medications function by mimicking the activity of the naturally occurring hormone GLP-1, which helps regulate blood sugar and decrease appetite. The efficacy of GLP-1 treatments in promoting significant weight loss and improving metabolic health has been demonstrated in numerous clinical trials, with some patients experiencing double-digit weight loss percentages.

Top 5 Holdings
Eli Lilly & Co logo
Novo Nordisk A/S logo
Innovent Biologics Inc logo
Zealand Pharma A/S logo
Chugai Pharmaceutical Co Ltd logo

(as of 05/21/2024)

All Holdings

as of TBD

Choose a Brokerage

Back
Choose a brokerage

Choose a Fund